Rapport Therapeutics, Inc.
About Rapport Therapeutics, Inc.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $20.0M
- Net income
- -$111.5M
- Total assets
- $512.4M
- Market cap
- $1.7B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $125.1M
- Operating income
- -$125.1M
- Income tax
- $0
- Net income
- -$111.5M
- EPS (basic)
- $-2.86
- EPS (diluted)
- $-2.86
Balance sheet
- Total assets
- $512.4M
- Current assets
- $498.6M
- Total liabilities
- $27.8M
- Current liabilities
- $19.0M
- Shareholders’ equity
- $484.7M
Cash flow
- Operating cash flow
- -$87.5M
- Investing cash flow
- -$187.5M
- Financing cash flow
- $270.8M
- Net cash flow
- -$4.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.7B
- EPS (diluted)
- $-2.86
- Shares outstanding
- 47.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 7, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $111.5M in FY2026.
- Trading 8% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Rapport Therapeutics, Inc..
Write a review
News about Rapport Therapeutics, Inc.
News & sentiment via Polygon.io
